Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc reports that interest due for May 2026 under its credit agreement with Perceptive Credit Holdings III, LP will be capitalised and added to the outstanding principal. Perceptive has also granted a limited waiver related to Section 8.15 of the credit agreement for June 2026.
Trinity Biotech plc is registering 675,048,580 ordinary shares, represented by 33,752,429 ADSs, for resale by the Selling Securityholder under a standby equity purchase agreement. The filing amends the Form F-1 to update fiscal year 2025 information and notes that 1,530,537 ADSs (representing 30,610,740 ordinary shares) have been sold by the Selling Securityholder to date. The Registration Statement covers a secondary offering of ADSs (1 ADS = 20 ordinary shares) and confirms the Company will not receive proceeds from sales by the Selling Securityholder, although it may elect to sell ADSs to the investor for gross proceeds of up to $25,000,000 under the Purchase Agreement.
Trinity Biotech plc requests withdrawal of its Registration Statement on Form F-3 (File No. 333-295846), filed May 13, 2026, under Rule 477(a). The company states it will instead proceed by post-effective amendment to its existing Form F-1 (File No. 333-293717), declared effective March 3, 2026. The F-3 was not declared effective and no securities were issued or sold under it.
Trinity Biotech plc registers 675,048,580 ordinary shares (33,752,429 ADSs) for resale by YA II PN, LTD. This Post-Effective Amendment updates the Form F-1 to reflect fiscal year 2025 results and to register the remaining ADSs available for resale under a Standby Equity Purchase Agreement dated February 24, 2026.
The Purchase Agreement gives the company the option to sell up to $25,000,000 of ADSs to the investor at formulas tied to ADS VWAP (0.97x for a three Trading Day period or 0.95x for a one Trading Day period). The Company delivered 175,537 Commitment ADSs to the investor as part of the arrangement and, as of the prospectus date, the Selling Securityholder has sold 1,530,537 ADSs (representing 30,610,740 ordinary shares).
The prospectus states the Company will not receive proceeds from resales by the Selling Securityholder but may receive proceeds if and when it elects to sell ADSs to the investor under the Purchase Agreement. ADSs trade on Nasdaq under symbol TRIB; the prospectus quotes a Nasdaq closing price of $0.7321 per ADS on June 2, 2026.
Trinity Biotech plc is registering the resale of up to 167,950,998 ADSs, representing up to 3,359,019,957 Ordinary Shares, for sale by Perceptive-affiliated selling shareholders pursuant to conversion rights and a convertible note. These ADSs may be issued on conversion of Conversion Obligations (together, the "Conversion Documents") and sold from time to time by the Selling Shareholders; the Company will receive no cash proceeds from such resales. Conversions are subject to a Beneficial Ownership Cap of 9.9% and a conversion floor price of $0.5061 per ADS; the ADS ratio is 1 ADS = 20 Ordinary Shares. The prospectus discloses resale methods, potential dilution if conversions occur, Nasdaq listing symbol TRIB, and that conversion reduces the outstanding indebtedness under the Credit Agreement.
Trinity Biotech plc files a Form F-3 to register the resale of 33,752,429 ADSs, representing 675,048,580 ordinary shares, in a secondary offering by YA II PN, Ltd. The prospectus states the Company will receive no proceeds from sales by the Selling Securityholder under this registration.
The filing also describes a Standby Equity Purchase Agreement under which the Company may, at its option, sell up to $25,000,000 aggregate gross purchase price of ADSs to the investor; pricing is based on VWAP with stated multipliers. Nasdaq closing price per ADS on May 12, 2026 was $0.593. Ordinary shares outstanding shown are 405,017,380 (before resale) and an illustrative post-sale figure of 1,080,065,960 ordinary shares assuming issuance of all ADSs under the Purchase Agreement.
Trinity Biotech plc is registering a post-effective Form F-3 to convert its prior Form F-1 and to register for resale up to 167,950,998 ADSs, representing 3,359,019,957 Ordinary Shares, by Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. (together, "Perceptive").
The ADSs are issuable pursuant to conversion rights and a convertible note described as the "Conversion Documents." Conversions are subject to a 9.9% Beneficial Ownership Cap and a minimum floor conversion price of $0.5061 per ADS. The company will not receive cash proceeds from Selling Shareholder resales; conversions reduce outstanding Conversion Obligations.
Trinity Biotech named Jerry Lydon Head of North America Commercial Operations as its diagnostics business shifts from restructuring toward building revenue momentum and profitability on a leaner operating base. His role covers the North America portfolio and the New York reference lab, including pipeline products such as EpiCapture and PrePsia.
The company reported Q4 2025 revenue of $11.1 million, down from $15.9 million a year earlier, mainly due to disruptions in global HIV testing funding and manufacturing transitions. Despite lower sales, Q4 gross margin improved from 30.8% to 35.2%, though net loss widened slightly to $17.5 million, including a one‑off $10.0 million IFRS charge linked to modified Perceptive financing.
For 2025, revenue fell to $43.8 million from $61.6 million, with point‑of‑care and haemoglobin sales both declining during the transformation and market disruption. Full‑year gross margin rose from 34.8% to 38.6%, and net loss was $37.4 million. Adjusted EBITDA improved to a loss of $5.9 million versus a $11.3 million loss in 2024, reflecting early financial benefits from the Comprehensive Transformation Plan, including outsourced HIV manufacturing now scaled and expected to support margins from Q2 2026.
Trinity Biotech plc’s major creditor group, led by Perceptive Advisors, has updated its ownership and financing terms. The reporting persons now show beneficial ownership of 3,424,019,957 Class A Ordinary Shares, representing 9.9% of the class, largely through warrants and convertible instruments.
On April 30, 2026, Perceptive Credit Holdings III, L.P. agreed a Limited Waiver and Third Amendment to Trinity Biotech’s credit agreement, waiving certain financial covenant non-compliance and providing an additional $2.5 million term loan. At the same time, the senior Convertible Note was amended to raise the maximum principal amount convertible into ADSs from $60,000,000 to $72,500,000 and to reduce the minimum conversion price from $1.03 to $0.5061 per ADS. Related changes were made to the Conversion Rights Agreement. These securities are subject to a Beneficial Ownership Cap limiting how many shares the group can beneficially own at any time.